PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that the second drug in its development pipeline, CF102, will be intended for treatment of liver cancer (Hepatocellular Carcinoma). Preclinical trials conducted by the company have shown that CF102 performs well in the inhibition of liver cancer in animal models. In addition, It was proven that the A3 Adenosine receptor, which is the drug target, is over-expressed in liver cancer tumors. The company has recently developed an assay that enables, by means of a blood test, to determine the receptor level before treatment initiation.
